<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808312</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-402-3885</org_study_id>
    <nct_id>NCT02808312</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics of GS-9674 in Adults With Normal and Impaired Hepatic Function</brief_title>
  <official_title>A Phase 1 Open-Label, Parallel-Group, Adaptive, Single-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of GS-9674 in Subjects With Normal and Impaired Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the single-dose pharmacokinetics of
      GS-9674 in adults with impaired hepatic function relative to matched, healthy controls with
      normal hepatic function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: AUClast of GS-9674</measure>
    <time_frame>Predose and up to 96 hours postdose</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: AUCinf of GS-9674</measure>
    <time_frame>Predose and up to 96 hours postdose</time_frame>
    <description>AUCinf is defined as the concentration of drug extrapolated to infinite time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Cmax of GS-9674</measure>
    <time_frame>Predose and up to 96 hours postdose</time_frame>
    <description>Cmax is defined as the maximum concentration of drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: %AUCexp of GS-9674</measure>
    <time_frame>Predose and up to 96 hours postdose</time_frame>
    <description>%AUCexp is defined as the percentage of area under the curve (AUC) extrapolated between AUClast and AUCinf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Clast of GS-9674</measure>
    <time_frame>Predose and up to 96 hours postdose</time_frame>
    <description>Clast is defined as the last observable concentration of drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Tmax of GS-9674</measure>
    <time_frame>Predose and up to 96 hours postdose</time_frame>
    <description>Tmax is defined as the time (observed time point) of Cmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Tlast of GS-9674</measure>
    <time_frame>Predose and up to 96 hours postdose</time_frame>
    <description>Tlast is defined as the time (observed time point) of Clast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: λz of GS-9674</measure>
    <time_frame>Predose and up to 96 hours postdose</time_frame>
    <description>λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: CL/F of GS-9674</measure>
    <time_frame>Predose and up to 96 hours postdose</time_frame>
    <description>CL/F is defined as the apparent oral clearance following administration of the drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Vz/F of GS-9674</measure>
    <time_frame>Predose and up to 96 hours postdose</time_frame>
    <description>Vz/F is defined as the apparent volume of distribution of the drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: t1/2 of GS-9674</measure>
    <time_frame>Predose and up to 96 hours postdose</time_frame>
    <description>t1/2 is defined as the estimate of the terminal elimination half-life of the drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidences of Adverse Events</measure>
    <time_frame>Up to 30 days posttreatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Pharmacodynamic (PD) Markers such as FGF19 and C4</measure>
    <time_frame>Predose and up to 96 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Nonalcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>Mild Hepatic Impairment (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild hepatic impairment and matched healthy controls will receive a single dose of GS-9674 (30 mg) on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impairment (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of GS-9674 (30 mg) on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Hepatic Impairment (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe hepatic impairment and matched healthy controls will receive a single dose of GS-9674 (10 mg) on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9674 (30 mg)</intervention_name>
    <description>GS-9674 30 mg (3 x 10 mg tablet) orally</description>
    <arm_group_label>Mild Hepatic Impairment (Cohort 1)</arm_group_label>
    <arm_group_label>Moderate Hepatic Impairment (Cohort 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9674 (10 mg)</intervention_name>
    <description>GS-9674 10 mg (1 x 10 mg tablet) orally</description>
    <arm_group_label>Severe Hepatic Impairment (Cohort 3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        Cohort 1:

          -  Individuals with mildly impaired and normal hepatic function.

          -  Individuals with mild hepatic impairment must have a score of 5-6 on the CPT
             Classification at Screening without evidence of worsening clinical and/or laboratory
             signs of hepatic impairment within 2 months prior or within the screening period.

        Cohort 2:

          -  Individuals with moderately impaired and normal hepatic function.

          -  Individuals with moderate hepatic impairment must have a score of 7-9 on the CPT
             Classification at Screening without evidence of worsening clinical and/or laboratory
             signs of hepatic impairment within 2 months prior or within the screening period.

        Cohort 3:

          -  Individuals with severely impaired and normal hepatic function.

          -  Individuals with severe hepatic impairment must have a score of 10-15 on the CPT
             Classification at Screening without evidence of worsening clinical and/or laboratory
             signs of hepatic impairment within 2 months prior or within the screening period.

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Study Team</last_name>
    <email>402-3885@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <zip>1640</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

